Study of tagraxofusp, azacitidine, and venetoclax for secondary AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people newly diagnosed with a type of acute myeloid leukemia (AML) that has developed after treatment with certain prior drugs (hypomethylating agents). The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new diagnosis of acute myeloid leukemia (AML) that has not been treated yet.
- Your leukemia cells must have a specific protein called CD123 on their surface (tested by a central lab).
- You must have had a prior bone marrow condition (MDS, CMML, or MPN) and received at least 2 cycles of a type of drug called a hypomethylating agent (like azacitidine or decitabine).
- Your white blood cell count must be below 30 x 10⁹/L before starting study treatment (can be lowered with other medicines first).
- You must be 18 years or older, have good organ function (including a heart pumping test of at least 45%), and be able to care for yourself (ECOG performance status 0-2).
- You cannot have had tagraxofusp before, or have a different type of leukemia (like acute promyelocytic leukemia), or have active infections or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.